Apellis Pharmaceuticals, Inc. (APLS)Healthcare | Biotechnology | Waltham, United States | NasdaqGS
40.90 USD
+0.03
(0.073%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 40.92 +0.02 (0.049%) ⇧ (April 17, 2026, 7:52 p.m. EDT) Short-term: ★★★★☆ | Long-term: ★★★☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 1:18 a.m. EDT
APLS is at a 140% multi-year high, likely driven by the Biogen acquisition rumors, but the market is pricing in exactly $41/cash. The options market is crowded here, with 177% more put volume than call volume, creating a high-probability ceiling. Traders should treat the 52-week high as a hard ceiling now; the momentum is short-lived and risk-adjusted returns are poor as the acquisition process plays out. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.222371 |
| AutoARIMA | 0.222371 |
| MSTL | 0.223003 |
| AutoTheta | 0.225214 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 31% |
| H-stat | 179.26 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.027 |
| Excess Kurtosis | -0.78 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 128.154 |
| Revenue per Share | 7.957 |
| Market Cap | 5,228,722,688 |
| Trailing P/E | 227.22 |
| Forward P/E | -167.45 |
| Beta | -0.20 |
| Profit Margins | 2.23% |
| Website | https://apellis.com |
As of April 19, 2026, 1:18 a.m. EDT: Options flow shows distinct skew. Calls display a massive volume and Open Interest (OI) spike at the $41 strike (At-The-Money), effectively acting as a valuation cap. However, Puts exhibit significantly higher volume (814 bulk vs 416 bulk total calls) and OI (9.9k vs ~10k), with a defensive wall at $39-$40. This imbalance suggests net hedging by shareholders selling into the upside or heavy speculative buying of downside protection, indicating strong resistance at current levels and potential for a trend reversal lower if news disappoints.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.2684414 |
| Address1 | 100 Fifth Avenue |
| All Time High | 94.75 |
| All Time Low | 11.45 |
| Ask | 44.16 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 2.8 - Hold |
| Average Daily Volume10 Day | 5,312,910 |
| Average Daily Volume3 Month | 5,118,256 |
| Average Volume | 5,118,256 |
| Average Volume10Days | 5,312,910 |
| Beta | -0.197 |
| Bid | 37.61 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 2.923 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 40.9 |
| Current Ratio | 3.136 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 40.95 |
| Day Low | 40.85 |
| Debt To Equity | 128.154 |
| Display Name | Apellis Pharmaceuticals |
| Earnings Call Timestamp End | 1,771,939,800 |
| Earnings Call Timestamp Start | 1,771,939,800 |
| Earnings Timestamp | 1,771,939,800 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda | 56,985,000 |
| Ebitda Margins | 0.05677 |
| Enterprise To Ebitda | 91.863 |
| Enterprise To Revenue | 5.215 |
| Enterprise Value | 5,234,817,024 |
| Eps Current Year | -1.127 |
| Eps Forward | -0.24425 |
| Eps Trailing Twelve Months | 0.18 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 25.5209 |
| Fifty Day Average Change | 15.379101 |
| Fifty Day Average Change Percent | 0.6026081 |
| Fifty Two Week Change Percent | 126.84415 |
| Fifty Two Week High | 40.95 |
| Fifty Two Week High Change | -0.049999237 |
| Fifty Two Week High Change Percent | -0.0012209825 |
| Fifty Two Week Low | 16.1 |
| Fifty Two Week Low Change | 24.800001 |
| Fifty Two Week Low Change Percent | 1.5403727 |
| Fifty Two Week Range | 16.1 - 40.95 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,510,237,800,000 |
| Float Shares | 83,244,115 |
| Forward Eps | -0.24425 |
| Forward P E | -167.45139 |
| Free Cashflow | -15,464,500 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 733 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.60341 |
| Gross Profits | 605,692,032 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.13737 |
| Held Percent Institutions | 0.90654 |
| Implied Shares Outstanding | 127,841,632 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts. |
| Long Name | Apellis Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 5,228,722,688 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_106524288 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 22,388,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 5,228,722,748 |
| Number Of Analyst Opinions | 15 |
| Open | 40.86 |
| Operating Cashflow | 45,327,000 |
| Operating Margins | -0.25582 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 617 977 5700 |
| Post Market Change | 0.019996643 |
| Post Market Change Percent | 0.048891544 |
| Post Market Price | 40.92 |
| Post Market Time | 1,776,469,927 |
| Previous Close | 40.87 |
| Price Eps Current Year | -36.29104 |
| Price Hint | 2 |
| Price To Book | 13.992474 |
| Price To Sales Trailing12 Months | 5.209022 |
| Profit Margins | 0.0223 |
| Quick Ratio | 2.586 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | hold |
| Recommendation Mean | 2.8 |
| Region | US |
| Regular Market Change | 0.0300026 |
| Regular Market Change Percent | 0.0734098 |
| Regular Market Day High | 40.95 |
| Regular Market Day Low | 40.85 |
| Regular Market Day Range | 40.85 - 40.95 |
| Regular Market Open | 40.86 |
| Regular Market Previous Close | 40.87 |
| Regular Market Price | 40.9 |
| Regular Market Time | 1,776,456,001 |
| Regular Market Volume | 5,188,378 |
| Return On Assets | 0.03534 |
| Return On Equity | 0.07479 |
| Revenue Growth | -0.059 |
| Revenue Per Share | 7.957 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 127,841,632 |
| Shares Percent Shares Out | 0.1965 |
| Shares Short | 25,123,090 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 22,934,760 |
| Short Name | Apellis Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.2578 |
| Short Ratio | 3.98 |
| Source Interval | 15 |
| State | MA |
| Symbol | APLS |
| Target High Price | 41.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 40.93333 |
| Target Median Price | 41.0 |
| Total Cash | 467,785,984 |
| Total Cash Per Share | 3.659 |
| Total Debt | 474,360,000 |
| Total Revenue | 1,003,782,016 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.18 |
| Trailing P E | 227.22223 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 23.896875 |
| Two Hundred Day Average Change | 17.003126 |
| Two Hundred Day Average Change Percent | 0.7115209 |
| Type Disp | Equity |
| Volume | 5,188,378 |
| Website | https://apellis.com |
| Zip | 2,451 |